title: 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy.
abstract: Around 20-30% of patients with hepatic metastasis from colorectal cancer can undergo liver resection, but the increased response rate obtained with the addition of monoclonal antibodies to chemotherapy regimens could result in a higher rate of liver surgery. In this report we describe the case of a patient who underwent a liver resection after neoadjuvant treatment with capecitabine, oxaliplatin and bevacizumab and who achieved a complete pathological response of the liver metastasis. A preoperative CT scan demonstrated a partial response to the treatment while 18FDG-PET scan correctly evaluated the complete pathological response in the liver and detected an active interaortocaval lymph node metastasis. New specific studies are required to evaluate the imaging response in metastatic colorectal cancer patients especially after treatment with new, targeted agents.
authors.affiliation: Medical Oncology Unit, S Orsola-Malpighi Hospital, Bologna, Italy. chiarafunaioli@yahoo.it
authors.forename: Chiara
authors.initials: C
authors.lastname: Funaioli
authors.forename: Carmine
authors.initials: C
authors.lastname: Pinto
authors.forename: Francesca
authors.initials: F
authors.lastname: Di Fabio
authors.forename: Donatella
authors.initials: D
authors.lastname: Santini
authors.forename: Claudio
authors.initials: C
authors.lastname: Ceccarelli
authors.forename: Emilio
authors.initials: E
authors.lastname: De Raffaele
authors.forename: Stefano
authors.initials: S
authors.lastname: Fanti
authors.forename: Paolo
authors.initials: P
authors.lastname: Castellucci
authors.forename: Ciro
authors.initials: C
authors.lastname: Longobardi
authors.forename: Federico
authors.initials: F
authors.lastname: Buggi
authors.forename: Andrea Angelo
authors.initials: AA
authors.lastname: Martoni
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D000069287:Capecitabine; D003110:Colonic Neoplasms / Q000473:pathology*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D019788:Fluorodeoxyglucose F18; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D049268:Positron-Emission Tomography / Q000379:methods; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D019275:Radiopharmaceuticals; D000077150:Oxaliplatin; D003841:Deoxycytidine; D019788:Fluorodeoxyglucose F18; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil